Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3105-3112

  Arakawa Todo, Maki ^a   Ueyama, Jun ^b   Nomura, Hiroshi ^b   Abe, Fumie ^c   Tsukiyama, Ikuto ^a   Matsuura, Katsuhiko ^a   Hasegawa, Takaaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

(Abcc2); Biliary excretion; Cimetidine; Drug interaction; Multidrug resistance associated protein 2 (Mrp2); Pharmacokinetics; Sunitinib

Indexed keywords

CIMETIDINE; CYTOCHROME P450 3A4; SODIUM CHLORIDE; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG TRANSPORT; HYPERBILIRUBINEMIA; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; STEADY STATE; TREATMENT DURATION;

(ABCC2); BILIARY EXCRETION; CIMETIDINE; DRUG INTERACTION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN-2 (MRP2); PHARMACOKINETICS; SUNITINIB;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; CIMETIDINE; DRUG INTERACTIONS; HYPERBILIRUBINEMIA; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; PYRROLES; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY;

EID: 84883291650     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chandra P and Brouwer KLR: The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm Res 21: 719-735, 2004.
2. Christensen JG: A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18: 3-10, 2007.
3. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R and Pazdur R: Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12: 107-113, 2007.
4. Duckett DR and Cameron MD: Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 6: 1175-1193, 2010.
5. Tang SC, Lagas JS, Lankheet NA, Polle B, Hilleband MJ, Rosing H, Beijnen JH and Schinkel AH: Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCC2) and can be enhanced by oral elacridar and sunitinib co-administration. Int J Cancer 130: 223-233, 2012.
6. Tang SC, Lankheet NAG, Poller B, Wagnenaar E, Beijnen JH and Schinkel AH: P-Glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther 341: 164-173, 2012.
7. Shukla S, Robey RW, Bates SE and Ambudkar SV: Shukla S, Robey RW, Bates SE and Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37: 359-365, 2009.
8. Crome P, Curl B, Holt D, Volans GN, Bennett PN and Cole DS: Digoxin and cimetidine: Investigation of the potential for a drug interaction. Hum Toxicol 4: 391-399, 1985.
9. Pan BF, Dutt A and Nelson JA: Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. J Pharmacol Exp Ther 270: 1-7, 1994.
10. Taur JS and Rodriquez-Proteau R: Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica 38: 1536-1550, 2008.
11. Natori T, Sata M, Nagai R and Makuuchi M: Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother 59: 56-60, 2005.
12. Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergard J, Luke M, Stimpel H and Sparso BH: Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 38: 514-518, 1995.
13. Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, King DW, Lubowski DZ and Morris DL: Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumorassociated lymphocytes. Cancer 85: 1658-1663, 1999.
14. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H and Okamoto T: Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 86: 161-167, 2002.
15. Inhorn L, Williams SD, Nattam S and Stephens D: High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study. Am J Clin Oncol 15: 157-159, 1992.
16. Sagaster P, Micksche M, Flamm J and Ludwig H: Randomised study using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 6: 999-1003, 1995.
17. Kinouchi T, Saiki S, Maeda O, Kuroda M, Usami M and Kotake T: Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-α and cimetidine. J Urol 157: 1604-1607, 1997.
18. Ito Y, Suzuki H, Hirohashi T, Kume K, Shimizu T and Sugiyama Y: Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Pathol 272: 16-22, 1997.
19. Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH and Huitema AD: Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 27: 466-476, 2013.
20. Kim A, Balis FM and Widemann BC: Sorafenib and sunitinib. Oncologist 14: 800-805, 2009.
21. Bello C, Houk B, Sherman L, Misbah S, Sarapa N, Smeraglia J and Haung X: Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers. J Clin Oncol 23: 3078, 2005.
22. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T and Sugiyama Y: Hepatic expression of multidrug resistanceassociated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol Pharmacol 53: 1068-1075, 1998.
23. Akita H, Suzuki H and Sugiyama Y: Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm Res 18: 1119-1125, 2001.
24. Newton DJ, Wang RW and Evans DC: Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2- deficient TR and EHBR rats. Life Sci 77: 1106-1115, 2005.
25. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G and Nooter K: Imatinib mesylate (ST1571) is a substrate for the breast cancer resistance protein (BCRP/ABCG2) drug pump. Blood 104: 2940-2942, 2004.
26. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang- Peng J and Yang PC: Gefitinib reverses chemotherapy chemotherapy resistance in gefitinib-insensitive multidrugresistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 6943-6949, 2005.
27. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U and Neubauer A: Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21: 1267-1275, 2007.
28. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr., Fu LW, Ambudkar SV and Chen ZS: Erlotinib ('Tarceva', OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 65: 1541-1546, 2007.
29. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG and Ashby CR: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATPbinding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914, 2008.
30. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP and White DL: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res 14: 3881-3888, 2008.
31. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A and Baker SD: Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenibglucuronide. Clin Cancer Res 19: 1458-1466, 2013.
32. Kuroda M, Kobayashi Y, Tanaka Y, Itani T, Mifuji R, Araki J, Kaito M and Adachi Y: Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats. J Gastroenterol Hepatol 19: 146-153, 2004.